Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer

Alex J. Walsh, Rebecca S. Cook, Melinda E. Sanders, Luigi Aurisicchio, Gennaro Ciliberto, Carlos L. Arteaga, Melissa C. Skala

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging of organoids derived from primary tumors can predict the therapeutic response of xenografts and measure antitumor drug responses in human tumor-derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and lifetime of NADH and FAD, coenzymes of metabolism. As early as 24 hours after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of responsive organoids decreased (P <0.001) and was further reduced when effective therapies were combined (P <5 ×10

Original languageEnglish
Pages (from-to)5184-5194
Number of pages11
JournalCancer Research
Volume74
Issue number18
DOIs
Publication statusPublished - Aug 6 2014

Fingerprint

Organoids
Optical Imaging
Breast Neoplasms
Pharmaceutical Preparations
Neoplasms
Flavin-Adenine Dinucleotide
Coenzymes
Heterografts
Antineoplastic Agents
NAD
Therapeutics
Fluorescence
Technology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Walsh, A. J., Cook, R. S., Sanders, M. E., Aurisicchio, L., Ciliberto, G., Arteaga, C. L., & Skala, M. C. (2014). Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Research, 74(18), 5184-5194. https://doi.org/10.1158/0008-5472.CAN-14-0663

Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. / Walsh, Alex J.; Cook, Rebecca S.; Sanders, Melinda E.; Aurisicchio, Luigi; Ciliberto, Gennaro; Arteaga, Carlos L.; Skala, Melissa C.

In: Cancer Research, Vol. 74, No. 18, 06.08.2014, p. 5184-5194.

Research output: Contribution to journalArticle

Walsh, Alex J. ; Cook, Rebecca S. ; Sanders, Melinda E. ; Aurisicchio, Luigi ; Ciliberto, Gennaro ; Arteaga, Carlos L. ; Skala, Melissa C. / Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. In: Cancer Research. 2014 ; Vol. 74, No. 18. pp. 5184-5194.
@article{7e0fe045a8654894b24829a0841affbb,
title = "Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer",
abstract = "There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging of organoids derived from primary tumors can predict the therapeutic response of xenografts and measure antitumor drug responses in human tumor-derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and lifetime of NADH and FAD, coenzymes of metabolism. As early as 24 hours after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of responsive organoids decreased (P <0.001) and was further reduced when effective therapies were combined (P <5 ×10",
author = "Walsh, {Alex J.} and Cook, {Rebecca S.} and Sanders, {Melinda E.} and Luigi Aurisicchio and Gennaro Ciliberto and Arteaga, {Carlos L.} and Skala, {Melissa C.}",
year = "2014",
month = "8",
day = "6",
doi = "10.1158/0008-5472.CAN-14-0663",
language = "English",
volume = "74",
pages = "5184--5194",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer

AU - Walsh, Alex J.

AU - Cook, Rebecca S.

AU - Sanders, Melinda E.

AU - Aurisicchio, Luigi

AU - Ciliberto, Gennaro

AU - Arteaga, Carlos L.

AU - Skala, Melissa C.

PY - 2014/8/6

Y1 - 2014/8/6

N2 - There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging of organoids derived from primary tumors can predict the therapeutic response of xenografts and measure antitumor drug responses in human tumor-derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and lifetime of NADH and FAD, coenzymes of metabolism. As early as 24 hours after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of responsive organoids decreased (P <0.001) and was further reduced when effective therapies were combined (P <5 ×10

AB - There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging of organoids derived from primary tumors can predict the therapeutic response of xenografts and measure antitumor drug responses in human tumor-derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and lifetime of NADH and FAD, coenzymes of metabolism. As early as 24 hours after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of responsive organoids decreased (P <0.001) and was further reduced when effective therapies were combined (P <5 ×10

UR - http://www.scopus.com/inward/record.url?scp=84907494553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907494553&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0663

DO - 10.1158/0008-5472.CAN-14-0663

M3 - Article

C2 - 25100563

AN - SCOPUS:84907494553

VL - 74

SP - 5184

EP - 5194

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 18

ER -